---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-031247"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2026-09-25T21:05:32+00:00"
generated_at: "2026-10-12T13:26:48.937719+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma FY2026 revenue falls 19.3% to $43.9M; swings to $2.8M net loss from $0.8M income

## Summary
- Q4 revenue $9.8M vs $14.2M a year earlier, down $4.4M or 31.0%; Q4 operating loss $0.9M vs $0.6M operating income.
- FY2026 operating loss ~$2.7M vs FY2025 operating income $2.0M; Q4 gross profit collapsed to $28K from $1.47M.
- FY net loss ~$2.8M (-$0.09/share) vs FY2025 net income ~$0.8M ($0.03/share); Q4 net loss ~$1.4M (-$0.04 vs -$0.01).
- Co-CEOs Riva Sheppard and Christina Kay: two largest Contract Manufacturing customers were ~90% of FY2026 revenue, up from 84% in FY2025.
- FY2026 income tax expense of $0.3M recorded despite pre-tax loss of $2.6M; weighted average shares 31.06M.

## SEC filing metadata
- accession: 0001437749-26-031247
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2026-09-25T21:05:32+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031247/0001437749-26-031247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031247/inbp20260925_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-031247
- JSON: https://secwatch.observer/filing/0001437749-26-031247.json
- Plain text: https://secwatch.observer/filing/0001437749-26-031247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.